Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
164.17M | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | Gross Profit |
79.76M | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | EBIT |
-34.51M | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | EBITDA |
-23.09M | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | Net Income Common Stockholders |
-97.52M | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
159.01M | 72.87M | 86.33M | 94.39M | 98.32M | 184.94M | Total Assets |
278.99M | 270.63M | 349.13M | 347.54M | 365.61M | 330.71M | Total Debt |
0.00 | 29.04M | 30.89M | 19.24M | 20.88M | 21.37M | Net Debt |
-89.04M | -43.83M | -55.44M | -75.15M | -74.94M | -136.10M | Total Liabilities |
15.38M | 58.37M | 63.56M | 60.45M | 93.20M | 42.33M | Stockholders Equity |
263.61M | 212.26M | 285.56M | 287.08M | 272.40M | 288.38M |
Cash Flow | Free Cash Flow | ||||
-808.00K | -7.21M | -3.08M | 3.25M | 11.44M | 34.18M | Operating Cash Flow |
7.46M | -1.79M | 4.41M | 8.40M | 13.06M | 37.01M | Investing Cash Flow |
-8.87M | -5.43M | -7.49M | -3.12M | -71.26M | 39.69M | Financing Cash Flow |
-7.03M | -6.32M | -4.85M | -6.78M | -3.77M | -8.14M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $3.39B | 26.55 | 14.06% | ― | 8.14% | 2.55% | |
58 Neutral | $710.91M | ― | -24.20% | ― | 10.40% | 78.94% | |
52 Neutral | $184.07M | ― | -9.15% | ― | 1.26% | 70.30% | |
51 Neutral | $245.90M | ― | -43.31% | ― | 0.52% | -295.83% | |
49 Neutral | $407.97M | ― | 87.26% | ― | ― | -817.72% | |
49 Neutral | $653.24M | ― | -22.87% | ― | 7.08% | 20.45% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% |
Anika Therapeutics has strategically shifted its focus by divesting Arthrosurface and planning to sell Parcus Medical, aiming to concentrate on its core hyaluronic acid technology and expanding Regenerative Solutions portfolio. The sale of Arthrosurface to Phoenix Brio was completed for $10 million, including a promissory note and potential sales-based consideration. Anika’s efforts are part of a broader strategy to streamline operations and enhance growth in the orthopedic market, estimated at $4 billion globally.